For Q1 FY2026 ended March 31, 2026, Xeris Biopharma reported revenue of $83.1 million, up 38.3% year-over-year. Net income was $2.2 million, a significant improvement from a net loss in the prior year. Operating income reached $7.9 million, and diluted EPS was $0.01. The company held $111.8 million in cash and had long-term debt of $221.2 million.
•Revenue grew 38.3% YoY to $83.1 million.
•Net income of $2.2 million vs. a loss of $9.1 million in Q1 FY2025.
•Operating income of $7.9 million, up 356% YoY.
•Cash and equivalents of $111.8 million; long-term debt of $221.2 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company develops and commercializs therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients.
Its portfolio also includes Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. Incorporated in 2005, the company is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for chronic endocrine and neurological diseases. Its main products include Gvoke, a ready-to-use liquid-stable glucagon for treating severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia in adult patients with Cushing's syndrome. The company is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine currently in phase 3 clinical trials for hypothyroidism. Xeris focuses on providing innovative treatments for conditions with limited options.
Where is Xeris Biopharma Holdings, Inc. headquartered and what markets does it serve?
Xeris Biopharma Holdings, Inc. is headquartered in Chicago, Illinois, United States. The company primarily serves the U.S. market, as indicated by its description summary focusing on treatments approved and marketed in the United States. Its products address conditions such as severe hypoglycemia, primary periodic paralysis, and Cushing's syndrome, which affect patients in the U.S. and potentially other regions. The company's operations are based in the U.S., and it is listed on the NasdaqGS exchange, reflecting its primary market focus.
What sector and industry does Xeris Biopharma Holdings, Inc. operate in?
Xeris Biopharma Holdings, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the research, development, and commercialization of pharmaceutical products, focusing on specialty drugs that treat specific chronic conditions. As a specialty and generic drug manufacturer, Xeris targets niche therapeutic areas such as endocrinology and neurology, offering both branded and potentially generic-like treatments. Its products like Gvoke, Keveyis, and Recorlev are examples of specialty therapies for conditions with limited treatment options.
On which stock exchange is Xeris Biopharma Holdings, Inc. listed and what is its trading currency?
Xeris Biopharma Holdings, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol XERS. The company trades in U.S. Dollars (USD), which is the currency of its home country, the United States. Being listed on NasdaqGS provides the company with visibility among institutional and retail investors, and it is subject to the exchange's listing requirements. The use of USD facilitates trading for investors in the U.S. and internationally, as the dollar is a widely accepted global currency.
What are the main products in Xeris Biopharma's portfolio?
Xeris Biopharma's portfolio includes three main commercial products and one pipeline candidate. Gvoke is a ready-to-use liquid-stable glucagon for treating severe hypoglycemia in both pediatric and adult patients, offering a convenient alternative to traditional glucagon kits. Keveyis is a therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, a rare muscle disorder. Recorlev is a cortisol synthesis inhibitor for endogenous hypercortisolemia in adults with Cushing's syndrome. Additionally, XP-8121 is a once-weekly subcutaneous injection of levothyroxine in phase 3 trials for hypothyroidism, aiming to provide a less frequent dosing option.